Sobi has received market approval by the European Comission for Alprolix, a long-duration protein therapy that protects hemophilia B patients from uncontrolled bleeding.  With a focus on rare diseases, Swedish Orphan Biovitrum (Sobi) has clinical programmes in diseases like alkaptonuria, tyrosinaemia and hemophilia – a disease with which Sobi is particularly invested. Its candidate for hemophilia […]